Antibodies emerge as key focus for Kyowa Kirin

Kyowa Hakko Kirin (KHK) is applying the technologies brought together by the merger of Kyowa Hakko and Kirin Pharma to an expanding pipeline of antibody products.

More from Anticancer

More from Therapeutic Category